Gefitinib: a pharmacoeconomic profile of its use in patients with non small cell lung cancer EGFR+
Sacchi V. – Farmeconomia e percorsi terapeutici 2011; 12(2): 77-85
Cost-effectiveness evaluations of spinal neuromodulation with ziconotide continuous infusion in cancer pain in a real clinical practice
Zaniolo O, Iannazzo S, Patrucco GP, Bellini R. – Farmeconomia e percorsi terapeutici 2011; 12(2): 87-94
Tiotropium bromide in the routine care of gold stage II COPD patients: a pharmaeconomic evaluation
Zaniolo O, Carsi M, Iannazzo S. – Farmeconomia e percorsi terapeutici 2011; 12(2): 45-52
Estimation of economic consequences of gold guidelines adoption in the italian clinical practice
Zaniolo O, Bettoncelli G, Bosio G, Mantovani L, Pistelli R, Vaghi A, Villa M, Iannazzo S, Bamfi F, Frizzo V, Dal Negro RW. – Farmeconomia e percorsi terapeutici 2011; 12(1): 5-19
Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy
Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. – Eur Ann Allergy Clin Immunol 2011; 43(2): 45-53
Cost-effectiveness analysis of lhrh agonists in the treatment of metastatic prostate cancer in Italy
Iannazzo S, Pradelli L, Carsi M, Perachino M. – Value Health 2011; 14(1): 80-9
Pharmacoeconomic evaluation of the MF59–adjuvanted influenza vaccine in the elderly population in Italy
Iannazzo S. – J Prev Med Hyg 2011; 52(1):1-8
